|2.||Hypertension (High Blood Pressure)
|4.||Chronic Kidney Failure (Chronic Renal Failure)
|1.||Parving, Hans-Henrik: 73 articles (10/2015 - 01/2002)|
|2.||Makino, Hirofumi: 57 articles (01/2016 - 01/2002)|
|3.||Cooper, Mark E: 56 articles (12/2015 - 01/2002)|
|4.||Rossing, Peter: 48 articles (10/2015 - 07/2002)|
|5.||Tarnow, Lise: 45 articles (10/2015 - 07/2002)|
|6.||Tomino, Yasuhiko: 36 articles (11/2015 - 01/2002)|
|7.||Wada, Jun: 34 articles (01/2016 - 01/2002)|
|8.||Kelly, Darren J: 30 articles (01/2015 - 01/2002)|
|9.||Groop, Per-Henrik: 29 articles (05/2015 - 04/2003)|
|10.||Koya, Daisuke: 28 articles (12/2015 - 03/2003)|
|1.||Streptozocin (Streptozotocin)FDA Link
04/01/2014 - "A marked decrease of klotho expression was observed in the kidney of streptozotocin-induced diabetic rats (STZ rats) showing diabetic nephropathy. "
05/01/2014 - "Sequoyitol ameliorates diabetic nephropathy in diabetic rats induced with a high-fat diet and a low dose of streptozotocin."
06/01/2010 - "This study investigates whether prolonged administration of PTX (40 mg/kg, per oral) is effective in streptozotocin-induced diabetic nephropathy. "
01/01/2009 - "Gallotannin ameliorates the development of streptozotocin-induced diabetic nephropathy by preventing the activation of PARP."
06/01/2015 - "The present study was designed to elucidate the therapeutic mechanism of BBR in a type 2 diabetic nephropathy rat model induced by a high-fat diet and low-dose streptozotocin injection. "
|2.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/01/1993 - "Strict glycemic control, and ACE inhibitors may be beneficial in early stages of diabetic nephropathy. "
01/01/2005 - "As in other causes of non-diabetic kidney disease, antihypertensive regimens with ACE inhibitors are more effective in lowering urine protein excretion in patients with advanced PKD compared to regimens without ACE inhibitors, and this benefit is greater in patients with higher levels of baseline urine protein excretion. "
03/27/2013 - "ACE inhibitors and ARBs are now the mainstay of treatment for diabetic nephropathy. "
01/01/2003 - "ACE inhibitors are known to be effective in preventing the progression of diabetic nephropathy. "
07/01/2001 - "The two main treatment strategies for primary prevention of diabetic nephropathy are improved glycaemic control and blood pressure lowering, particularly using drugs such as angiotensin-converting enzyme inhibitors. "
|3.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
12/01/2010 - "A regimen using a maximally dosed angiotensin-converting enzyme inhibitor is safe and effective for achieving BP goal in high-risk, predominantly minority patients with diabetic nephropathy. "
03/01/1995 - "In patients with diabetic nephropathy, angiotensin converting enzyme (ACE) inhibition has been shown to be more effective in this regard than conventional antihypertensive therapy. "
09/07/1996 - "To evaluate the concept that an insertion/deletion polymorphism of the angiotensin converting enzyme gene predicts the therapeutic efficacy of inhibition of angiotensin converting enzyme on progression of diabetic nephropathy. "
04/01/1992 - "Angiotensin converting enzyme (ACE) inhibition has shown promising results in diabetic nephropathy, but long-term results on survival are not available. "
01/01/2011 - "Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition."
|4.||Insulin (Novolin)FDA Link
12/01/2004 - "Type I insulin dependent diabetic patients aged 45 or less with severe diabetic nephropathy, without immediate life saving cardiovascular risk, highly motivated and well informed achieve the best results. "
11/01/2011 - "Conversely, adoptive transfer of CD4(+)FoxP3(+) Tregs significantly improved insulin sensitivity and diabetic nephropathy. "
01/01/1993 - "To determine the mechanisms underlying diabetic nephropathy (DN) onset, a clinical and morphological study was initiated of 14 diabetics with insulin-dependent disease free of clinical renal manifestations. "
01/01/2013 - "This study was designed to evaluate the renoprotective effect of insulin on diabetic nephropathy through Rac1 inhibition. "
12/01/2012 - "This study was designed to check whether insulin supplementation is crucial for inducing diabetic nephropathy (DNP) in Wistar rats. "
|5.||Angiotensin Receptor AntagonistsIBA
01/01/2012 - "The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs). "
07/01/2012 - "This study aimed to investigate the beneficial effects of angiotensin receptor blockers (ARBs) on markers of endothelial function in patients with early stage of diabetic nephropathy (DN). "
03/01/2008 - "Clinical trials have found angiotensin receptor blockers (ARBs) to be more beneficial than traditional antihypertensive therapy in patients with type 2 diabetic nephropathy (DN). "
08/01/2005 - "Recent clinical trials have supported the use of angiotensin II receptor antagonists in the treatment of diabetic nephropathy, resulting in the approval of new therapeutic indications in the US and Europe. "
08/07/2004 - "Several studies have found that angiotensin-II receptor antagonists have a renoprotective effect in type 2 diabetics with diabetic nephropathy, independently of their antihypertensive effects. "
|6.||Glucose (Dextrose)FDA LinkGeneric
01/01/2015 - "There is a scarcity of studies analysing the nephroprotective effect of antihyperglycaemic drugs beyond their glucose lowering effect and improved glycaemic control on the prevention and progression of diabetic nephropathy. "
01/01/2015 - "Although these results suggest that DPP-4 inhibitors can protect against diabetic nephropathy, insufficient evidence is available to conclude that this class of agent directly prevents or decreases nephropathy in humans independently from improved glucose control. "
08/01/2011 - "Remission of diabetic nephropathy in type 2 diabetic Asian population: role of tight glucose and blood pressure control."
03/01/2008 - "Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control."
10/01/2006 - "These results suggest that EGCg ameliorates glucose toxicity and renal injury, thus alleviating renal damage caused by abnormal glucose metabolism-associated oxidative stress involved in renal lesions of diabetic nephropathy."
01/01/2008 - "In patients without underlying diabetic glomerulosclerosis, correlates of complete remission were younger age, female sex, lower serum creatinine at biopsy, and absence of immunocompromised state. "
01/01/2012 - "The creatinine clearance of group 3 was lower than those of groups 1 and 2. The amount of urine microalbumin and protein in group 1 were higher than those in groups 2 and 3. Also, more glomerulus basement membrane foot processes were preserved in groups 2 and 3. In conclusion, CSVA has beneficial preventive tendencies towards diabetic nephropathy in both in vitro and in vivo models."
01/01/2009 - "Gallotannin (20 mg/kg/day, i.p.) treatment for 4 weeks led to a significant reduction in the levels of plasma creatinine which is a well known marker for diabetic nephropathy. "
11/01/1997 - "Initial uptake is a semi-quantitative renographic parameter that can provide complementary information to biochemical data and it may be useful in the management of diabetic nephropathy, especially in patients with high serum creatinine or creatinine clearance."
05/05/2015 - "The diabetic 300% hypermorphs had ∼1/3 the creatinine clearance of wild-type mice, >20× their albumin excretion, ∼3× thicker glomerular basement membranes and severe podocyte effacement, matching human diabetic nephropathy. "
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/30/2007 - "We hypothesized that the vascular endothelial growth factor (VEGF) participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy because of the effect it has on VEGF. "
04/23/2004 - "We hypothesized that VEGF participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy through its effect on VEGF. "
01/01/2010 - "However, plasma VEGF levels in diabetic nephropathy patients are increased and blocking VEGF improved diabetic nephropathy in animal models. "
02/01/2006 - "Antagonism of vascular endothelial growth factor (VEGF) has improved the outcome in experimental nephropathies of various origins, including diabetic nephropathy in a type 1 diabetic rat model and a type 2 diabetic mouse model. "
04/01/2015 - "Our study suggests that I/D polymorphism in the promoter region of the VEGF gene is not associated with DN in type 2 diabetes patients, but might have a role in development of non-diabetic nephropathy."
12/01/2013 - "The EP1 receptor facilitates the actions of angiotensin II, thereby suggesting that targeting of both the renin-angiotensin system and the EP1 receptor could be beneficial in diabetic nephropathy."
11/13/2008 - "The study also implicates that angiotensin II (AngII)-Src-Smad1 signaling pathway has played a key role for development of diabetic nephropathy. "
01/01/2006 - "These and other studies indicate that angiotensin II antagonists not only improve survival and quality of life of patients with diabetic nephropathy, but also have the potential to reduce the substantial healthcare burden associated with managing these patients. "
07/01/2003 - "Lewis study has demonstrated renoprotective effect of ACE inhibitor in type-1 diabetic nephropathy, and RENAAL and IDNT has documented that of angiotensin II type-1 receptor blocker in type-2 diabetes. "
01/01/1997 - "This and other indirect evidence from experimental animal studies suggest that the intrarenal concentration of angiotensin II may be increased as a result of increased synthesis and despite enhanced breakdown, that this peptide participates in the progression of diabetic nephropathy. "
|10.||Blood Glucose (Blood Sugar)IBA
06/01/2001 - "Data from the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that near-normalization of blood glucose levels results in a significant reduction in the development and progression of diabetic nephropathy. "
01/01/2015 - "In summary, AC controls blood glucose, inhibits inflammatory and fibrotic processes, suppresses the TGF-β1/Smad signaling pathway, and activates phosphorylation of AMPKα in the kidneys, which confirms the protective effects of AC in the early stage of diabetic kidney disease."
10/07/2015 - "12 week administration of STJ improved the metabolic parameters associated with blood glucose and lipid and inhibited the TGF-β1 signaling pathway, which positively contributed to the amelioration of chronic diabetic kidney disease."
01/01/2014 - "It is suggested that protection against development of diabetic nephropathy by MgSO4 treatment involves changes in the blood glucose and oxidative stress."
12/01/1992 - "We conclude that adolescents and young adults in an early stage of diabetic nephropathy have reduced glomerular charge selectivity, which may be improved by reducing the mean blood glucose level."
06/24/2014 - "Renal transplantation has been established as a first line treatment for diabetic nephropathy unless there are major contraindications and provides not only a better quality of life, but also a significant survival advantage over dialysis. "
01/01/2011 - "The present study has been carried out to prove the efficacy of Ayurvedic drugs in the management of diabetic nephropathy, which can be helpful in reducing the need of dialysis and avoiding or delaying renal transplantation. "
03/01/2004 - "Today, simultaneous pancreas and kidney transplantation is the gold standard procedure for end-stage type 1 diabetic nephropathy recipients."
06/01/1984 - "Improved results of renal transplantation in diabetic nephropathy."
04/01/2015 - "This study aimed to compare the outcome of renal transplantation for type 2 diabetic nephropathy with that for nondiabetic nephropathy. "
|2.||Transplantation (Transplant Recipients)
11/05/2009 - "Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats."
11/01/2015 - "Previous studies have illustrated that bone marrow-derived mesenchymal stem cell (BMMSC) transplantation has therapeutic effects on diabetes and can prevent mice from renal damage and diabetic nephropathy (DN). "
11/05/2009 - "This study aimed to explore whether mesenchymal stem cells (MSCs) transplantation could attenuate diabetic nephropathy in experimental diabetic rats. "
07/01/2001 - "Immunohistochemical studies demonstrated that hypertrophic and fibrotic changes in pancreatic islets, together with mesangial proliferation of the glomerular matrix, an indicator for diabetic nephropathy, were attenuated predominantly in the IT group at the late phase after transplantation compared with those in the corresponding phase of the SO group. "
11/01/1998 - "The aim of our study was to assess the effects of transplantation of long-term cultured and cryopreserved fetal pancreas islets on metabolic control and the development of diabetic nephropathy. "
02/01/1995 - "Combined kidney and pancreas transplantation is a safe and effective treatment option for diabetic nephropathy. "
05/01/2001 - "Resolution of renal lesions (62%) has been claimed in a single study and in a small number of patients with diabetic nephropathy after 10-year pancreas transplantation. "
01/01/2013 - "Simultaneous kidney-pancreas transplantation (SKPT) is one of the most effective therapies for patients with type 1 DM and end-stage diabetic nephropathy. "
01/01/2013 - "The authors studied renal structure before and 5 and 10 years after pancreas transplantation in nonuremic patients with long-term type 1 diabetes, with established diabetic nephropathy lesions at baseline. "
01/01/2013 - "Pancreas transplantation and reversal of diabetic nephropathy lesions."
|4.||Renal Dialysis (Hemodialysis)
01/01/2008 - "Therapeutic options such as strict blood pressure and/or glycemic control are effective for preventing the development and progression of diabetic nephropathy, but the number of diabetic patients on hemodialysis is still increasing. "
01/01/2010 - "The aim of the present study was to find out any differences in the progression of macroangiopathic diseases and patient survival in diabetic patients with diabetic nephropathy (DN) or diabetic renal vasculopathy (DV) under hemodialysis therapy. "
06/01/2009 - "The present study reports the difficulties in early diagnosis of an extrapulmonary TBC case, as it happened to a 53-year-old man with diabetic nephropathy who started on regular hemodialysis for 5 months. "
02/01/2001 - "The purpose of this study is to clarify the role of diabetic nephropathy on outcomes of a group of patients on chronic hemodialysis undergoing CABG. "
09/01/2015 - "A 72-year-old female, with diabetic nephropathy, was on maintenance hemodialysis. "
|5.||Protein-Restricted Diet (Diet, Protein Restricted)
08/01/2001 - "Low and very low-protein diets associated with specific enteral supplements are indicated in most patients with chronic renal disease and in patients with incipient diabetic nephropathy to slow progression of disease and to improve their overall status, contributing to improved survival (grade A recommendation). "
02/01/2006 - "Reduction of urinary protein levels by various medications and a low-protein diet limits renal function decline in individuals with nondiabetic and diabetic nephropathies to the point that remission of the disease and regression of renal lesions have been observed in experimental animals and even in humans. "
01/01/2013 - "Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials."
09/01/2008 - "Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials."
07/01/1993 - "This study was designed to clarify the mechanisms by which the progression of diabetic nephropathy is inhibited by low-protein diet. "